XIAP and ovarian carcinoma: In order to most effectively target ovarian cancer cells and decrease systemic toxicities, the delivery of the XIAP antagonist has been rendered cancer selective by linking the SMAC mimetic to the sigma-2 ligand SW43, the receptors of which are upregulated in ovarian cancer cells [30].